Clinical Scorecard: Growth Hormone Treatment in Children Born Small for Gestational Age Affects Glucose-Insulin Metabolism Similar to Obesity-Related Impairments
At a Glance
Category
Detail
Condition
Impaired glucose-insulin metabolism in children born small for gestational age (SGA)
Key Mechanisms
Growth hormone (GH) therapy induces insulin resistance by counteracting insulin effects, increasing gluconeogenesis and glycogenolysis, and reducing glucose uptake in adipose tissue
Target Population
Children born SGA without catch-up growth receiving GH therapy, children with isolated growth hormone deficiency (iGHD), children with obesity, and lean controls
Care Setting
Pediatric endocrinology and metabolic monitoring in outpatient or specialized clinical settings
Key Highlights
SGA children under GH treatment exhibit insulin resistance levels approaching those of children with obesity.
Prediabetes prevalence is highest in GH-treated SGA children (11.11%) compared to iGHD (1.59%) and obesity (3.13%) cohorts.
After cessation of GH therapy, SGA patients retain elevated markers of prediabetes and insulin resistance similar to obese children.
Guideline-Based Recommendations
Diagnosis
Use oral glucose tolerance tests (OGTT) including Matsuda index and insulin area under the curve (AUC insulin) for comprehensive assessment of insulin resistance.
Assess fasting glucose, HOMA-IR, and HbA1c to monitor glucose-insulin metabolism.
Management
Administer recombinant human growth hormone therapy for SGA children lacking catch-up growth after age 4 years as per EMA approval.
Consider the risk of impaired glucose metabolism when initiating GH therapy in SGA children.
Monitoring & Follow-up
Perform close metabolic monitoring of glucose-insulin parameters during and after GH therapy in SGA patients.
Regularly assess HbA1c and insulin resistance markers to detect prediabetes early.
Risks
GH therapy may worsen insulin resistance and increase prediabetes risk in SGA children.
SGA children have an inherent higher risk of insulin resistance and metabolic disorders similar to obesity.
Patient & Prescribing Data
Children born SGA without catch-up growth receiving GH therapy
GH therapy improves growth but is associated with increased insulin resistance and higher prediabetes prevalence compared to iGHD and lean controls; metabolic effects persist after therapy cessation.
Clinical Best Practices
Screen SGA children for glucose-insulin metabolism impairments before and during GH treatment.
Use comprehensive metabolic testing beyond fasting parameters, including OGTT-derived indices.
Educate families about potential metabolic risks associated with GH therapy in SGA children.
Maintain long-term follow-up after GH therapy discontinuation to monitor persistent metabolic alterations.
Researchers found that patients with higher waist circumference and lower grip strength had the greatest risk for developing type 2 diabetes during long-term follow-up.
